Pan-KRAS Inhibitor ERAS-4001

**Semantic type:** Pharmacologic Substance

**Definition:** An orally bioavailable inhibitor that targets the oncogenic KRAS wild-type (WT) and various KRAS mutant forms, with potential antineoplastic activity. Upon oral administration, pan-KRAS inhibitor ERAS-4001 selectively targets and binds to KRAS, thereby inhibiting KRAS-dependent signaling. This inhibits the growth and survival of KRAS-overexpressing and mutated tumor cells. KRAS, a member of the RAS family of oncogenes, plays an important role in cell signaling, division and differentiation. Mutations of KRAS may induce constitutive signal transduction leading to tumor cell growth, proliferation, invasion, and metastasis.

**Synonyms:** - ERAS 4001 - ERAS-4001 - ERAS4001 - KRAS Inhibitor ERAS-4001